Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Nanobiotix SA (NANO) EUR0.03

Sell:€10.14 Buy:€10.36 Change: €0.15 (1.49%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Change: €0.15 (1.49%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Change: €0.15 (1.49%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nanobiotix SA is a France-based oncology-focused nanomedicine company. The Company is engaged in developing nanoparticle technology. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The Company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Contact details

60 rue de Wattignies
+33 (1) 40260470

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€351.04 million
Shares in issue:
34.81 million
Euronext Paris

Key personnel

  • Gary Phillips
    Independent Chairman of the Supervisory Board
  • Laurent Levy
    Chairman of the Management Board and Chief Executive Officer
  • Bart Van Rhijn
    Chief Financial Officer, Member of the Management Board
  • Alain Dostie
    Chief Operating Officer
  • Edwina Baskin-Bey
    Member of the Management Board, Medical Director
  • Elsa Borghi
    Member of the Management Board, Product Development & Innovation
  • Bernd Muehlenweg
    Member of the Management Board, Head of Business Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.